CRISPR Is Overcome When Viruses Gang Up on Bacteria

Phages that die during bacterial invasion help other viruses defeat the microbes’ immune responses.

Written byKerry Grens
| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Bacteria can fend off viral infections by chopping up their DNA with their CRISPR-based immune system, but sufficient numbers of phages can overwhelm microbes’ defenses. In two papers published in Cell today (July 19), scientists report that part of phages’ strategy appears to be an “altruistic” method of invasion, in which viral genomes that never succeed in replicating nonetheless impair bacterial immunity and facilitate infection by other viruses.

“This work shows that phages can work together to disable bacterial immune systems, and this has important implications for using phage to treat human infections, since the dose of phage that is used can determine whether the phage is able to kill the bacteria,”

Stineke van Houte, a coauthor of one of the studies and a researcher at the University of Exeter, says in a press release.

To understand how phages get past bacteria’s CRISPR systems, van Houte and her colleagues looked ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies